There was no formal evidence of publication bias for NASH resolution (P = 0.453) (Supplementary Fig. 9), improvement of NAS by  ≥ 2 points (P = 0.101) (Supplementary Fig. 10), fibrosis improvement  ≥ 1 stage (P = 0.451) (Supplementary Fig. 11), fibrosis progression (P = 0.105) (Supplementary Fig. 12), steatosis improvement (P = 0.312), ballooning improvement (P = 0.496), lobular inflammation improvement (P = 0.232), and biochemical response (P = 0.812 and P = 0.957 for AST and ALT, respectively). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.